POTOMAC: Durvalumab plus BCG boosts disease-free survival in NMIBC - Urology TimesYesterday • Google News
POTOMAC Trial at ESMO 2025: Durvalumab Plus BCG Improves Outcomes in High-Risk NMIBC - Oncodaily2 days ago • Google News